Cell Therapy Manufacturing Market (By Therapy Type: Allogenic Cell Therapy, Autologous Cell Therapy; By Technology Type: Somatic Cell Technology, Cell Immortalization Technology, Viral Vector Technology, Genome Editing Technology, Cell Plasticity Technology, 3D Technology; By Source: IPSC, Bone Marrow, Umbilical Cord, Adipose Tissues, Neural Stem; By Application) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2024-2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cell Therapy Manufacturing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cell Therapy Manufacturing Market, by Therapy Type, 2024-2033
8.1.1. Allogenic Cell Therapy
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Autologous Cell Therapy
8.1.2.1. Market Revenue and Forecast (2021-2033)
9.1. Cell Therapy Manufacturing Market, by Technology Type, 2024-2033
9.1.1. Somatic Cell Technology
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Cell Immortalization Technology
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Viral Vector Technology
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Genome Editing Technology
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Cell Plasticity Technology
9.1.5.1. Market Revenue and Forecast (2021-2033)
9.1.6. 3D Technology
9.1.6.1. Market Revenue and Forecast (2021-2033)
10.1. Cell Therapy Manufacturing Market, by Source, 2024-2033
10.1.1. IPSC (Induced Pluripotent Stem Cell)
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Bone Marrow
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. Umbilical Cord
10.1.3.1. Market Revenue and Forecast (2021-2033)
10.1.4. Adipose Tissues
10.1.4.1. Market Revenue and Forecast (2021-2033)
10.1.5. Neural Stem
10.1.5.1. Market Revenue and Forecast (2021-2033)
11.1. Cell Therapy Manufacturing Market, by Application, 2024-2033
11.1.1. Musculoskeletal
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Cardiovascular
11.1.2.1. Market Revenue and Forecast (2021-2033)
11.1.3. Gastrointestinal
11.1.3.1. Market Revenue and Forecast (2021-2033)
11.1.4. Neurological
11.1.4.1. Market Revenue and Forecast (2021-2033)
11.1.5. Oncology
11.1.5.1. Market Revenue and Forecast (2021-2033)
11.1.6. Dermatology
11.1.6.1. Market Revenue and Forecast (2021-2033)
11.1.7. Others
11.1.7.1. Market Revenue and Forecast (2021-2033)
12.1. North America
12.1.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.1.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.1.3. Market Revenue and Forecast, by Source (2021-2033)
12.1.4. Market Revenue and Forecast, by Application (2021-2033)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.1.5.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.1.5.3. Market Revenue and Forecast, by Source (2021-2033)
12.1.5.4. Market Revenue and Forecast, by Application (2021-2033)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.1.6.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.1.6.3. Market Revenue and Forecast, by Source (2021-2033)
12.1.6.4. Market Revenue and Forecast, by Application (2021-2033)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.2.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.2.3. Market Revenue and Forecast, by Source (2021-2033)
12.2.4. Market Revenue and Forecast, by Application (2021-2033)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.2.5.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.2.5.3. Market Revenue and Forecast, by Source (2021-2033)
12.2.5.4. Market Revenue and Forecast, by Application (2021-2033)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.2.6.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.2.6.3. Market Revenue and Forecast, by Source (2021-2033)
12.2.6.4. Market Revenue and Forecast, by Application (2021-2033)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.2.7.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.2.7.3. Market Revenue and Forecast, by Source (2021-2033)
12.2.7.4. Market Revenue and Forecast, by Application (2021-2033)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.2.8.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.2.8.3. Market Revenue and Forecast, by Source (2021-2033)
12.2.8.4. Market Revenue and Forecast, by Application (2021-2033)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.3.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.3.3. Market Revenue and Forecast, by Source (2021-2033)
12.3.4. Market Revenue and Forecast, by Application (2021-2033)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.3.5.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.3.5.3. Market Revenue and Forecast, by Source (2021-2033)
12.3.5.4. Market Revenue and Forecast, by Application (2021-2033)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.3.6.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.3.6.3. Market Revenue and Forecast, by Source (2021-2033)
12.3.6.4. Market Revenue and Forecast, by Application (2021-2033)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.3.7.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.3.7.3. Market Revenue and Forecast, by Source (2021-2033)
12.3.7.4. Market Revenue and Forecast, by Application (2021-2033)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.3.8.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.3.8.3. Market Revenue and Forecast, by Source (2021-2033)
12.3.8.4. Market Revenue and Forecast, by Application (2021-2033)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.4.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.4.3. Market Revenue and Forecast, by Source (2021-2033)
12.4.4. Market Revenue and Forecast, by Application (2021-2033)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.4.5.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.4.5.3. Market Revenue and Forecast, by Source (2021-2033)
12.4.5.4. Market Revenue and Forecast, by Application (2021-2033)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.4.6.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.4.6.3. Market Revenue and Forecast, by Source (2021-2033)
12.4.6.4. Market Revenue and Forecast, by Application (2021-2033)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.4.7.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.4.7.3. Market Revenue and Forecast, by Source (2021-2033)
12.4.7.4. Market Revenue and Forecast, by Application (2021-2033)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.4.8.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.4.8.3. Market Revenue and Forecast, by Source (2021-2033)
12.4.8.4. Market Revenue and Forecast, by Application (2021-2033)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.5.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.5.3. Market Revenue and Forecast, by Source (2021-2033)
12.5.4. Market Revenue and Forecast, by Application (2021-2033)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.5.5.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.5.5.3. Market Revenue and Forecast, by Source (2021-2033)
12.5.5.4. Market Revenue and Forecast, by Application (2021-2033)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Therapy Type (2021-2033)
12.5.6.2. Market Revenue and Forecast, by Technology Type (2021-2033)
12.5.6.3. Market Revenue and Forecast, by Source (2021-2033)
12.5.6.4. Market Revenue and Forecast, by Application (2021-2033)
13.1. Abbott
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Thermo Fisher Scientific
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Catalent, Inc
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. Bio-Techne
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Cytiva
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Lonza
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. The Discovery Labs
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Novartis AG
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Bristol-Myers Squibb Company
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. Gilead Sciences, Inc.
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample